Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.
Adding a second screening method finds more early cancer between mammograms but also leads to more false positives.
Abnormal anal screening results are common, but they often do not to lead to invasive cancer.
Smoking cessation, moderate drinking, a healthy diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer.
This malignancy, caused by human papillomavirus (HPV), can be prevented with a vaccine.
This is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
Successful treatment with direct-acting antivirals prolonged survival by 18 months.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.
People with liver cirrhosis often have substantial financial burden that interferes with their care.
Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
First targeted therapy may prolong survival of men with advanced prostate cancer.
Sci-B-Vac may offer more protection for older people and those with a weaker immune system.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.